![Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland | Business Wire Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland | Business Wire](https://mms.businesswire.com/media/20220705005255/en/1504255/22/Urovant_Pierre-Fabre_LogoLockup-01.jpg)
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland | Business Wire
![PIERRE FABRE GROUP Accelerating online growth with a global e-Retail upskilling programme - Artefact PIERRE FABRE GROUP Accelerating online growth with a global e-Retail upskilling programme - Artefact](https://www.artefact.com//wp-content/uploads/2021/06/pierre-fabre-laboratory.jpeg)
PIERRE FABRE GROUP Accelerating online growth with a global e-Retail upskilling programme - Artefact
![Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel) | Business Wire Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel) | Business Wire](https://mms.businesswire.com/media/20230207006101/en/1707786/5/MicrosoftTeams-image_%286%29.jpg)